Researchers reported a method to incorporate five distinct noncanonical amino acids (ncAAs) into a single protein in mammalian cells, marking a major expansion of the genetic code for complex protein engineering. The work combines orthogonal tRNA/synthetase systems and codon reassignment strategies to enable multi-site ncAA incorporation for sophisticated protein modifications. The team demonstrated simultaneous incorporation, validated by mass spectrometry and functional assays, and highlighted applications in multi-site labeling, protein therapeutics with enhanced properties, and synthetic biology circuits. Technical challenges addressed included cross-reactivity of translation components and suppression efficiency across multiple codons. This advance opens routes for designing proteins with multiple orthogonal chemistries—enabling tailored pharmacokinetics, targeted delivery handles, and novel modalities that standard amino acids cannot deliver. Authors noted scalability and regulatory considerations for therapeutic production remain to be solved. Biotech companies in biologics engineering, antibody–drug conjugates, and next-generation protein therapeutics should evaluate this platform for bespoke modifications; manufacturing and quality-control workflows will need updates to handle ncAA-containing products.